Clinical observation of perioperative hyperthermic intraperitonral chemotherapy on the 60 cases of patients with gastrointestinal cancer
10.3969/j.issn.1006-5725.2014.18.034
- VernacularTitle:60例胃肠癌患者围术期腹腔热灌注化疗的临床观察
- Author:
Gaofang ZHAN
;
Jinsong CHEN
;
Cuiyan YANG
- Publication Type:Journal Article
- Keywords:
Gastric neoplasms;
Colorectal cancer;
Hyperthermic intraperitonral chemotherapy;
Malignant ascites
- From:
The Journal of Practical Medicine
2014;(18):2967-2969
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the preliminary effect and safety of perioperative hyperthermic intraperitonral chemotherapy to treat gastrointestinal cancer. Methods The clinical data of 60 patients with progressed gastric or colorectal carcinoma who underwent perioperatively HIPEC in our hospital from May, 2012 to October, 2013 were retrospectively analyzed. The incision healing, complications, KPS scores and serum CEA levels were observed. Results The vital signs of all patients were normal during HIPEC. There was no perioperative death. No patients underwent serious complications like diffuse peritonitis, intestinal obstruction, gastrointestinal perforation or intraperitoneal bleeding. There was no anastomotic leakage in 28 patients who underwent Stomach-jejunum anastomosis or intestinal anastomosis. After HIPEC, the life quality was improved;increase in KPS score and reduction in serum CEA levels were noted in all patients (P < 0.01). Of 29 patients with malignant ascites, 20 cases achieved complete mitigation and 8 cases achieved partial mitigation, 1 case was in stable condition, thus yielding effective rate of 96.5%. Conclusions It is safe and feasible for HIPEC to treat gastrointestinal cancer. HIPEC can improve the patients’ life qualities, without theincrease in perioperative complications. The short-term effect of HIPEC is confirmed in alleviating ascites.
